Product
Maralixibat
Aliases
Formerly LUM001 and SHP625
7 clinical trials
6 indications
Indication
Biliary AtresiaIndication
Cholestatic Liver DiseaseIndication
Alagille syndromeIndication
Chronic Idiopathic ConstipationIndication
Cystic FibrosisClinical trial
Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After HepatoportoenterostomyStatus: Completed, Estimated PCD: 2023-11-07
Clinical trial
MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and Alagille SyndromeStatus: Active (not recruiting), Estimated PCD: 2023-08-22
Clinical trial
Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)Status: Recruiting, Estimated PCD: 2028-09-20
Clinical trial
MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFICStatus: Completed, Estimated PCD: 2022-09-01
Clinical trial
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot StudyStatus: Not yet recruiting, Estimated PCD: 2026-06-30